The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Income statements and balance sheets
The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for the fiscal year of 2022.
Disposition of the company's profit or loss
The general meeting resolved, in accordance with the board of directors' proposal, that no dividend is paid and that the company's funds available for distribution are carried forward.
Discharge from liability
The general meeting resolved to grant discharge from liability to all persons who have had the position of board member, CEO, or deputy CEO in the company during 2022.
Election of members of the board of directors and auditors
The general meeting resolved, in accordance with the nomination committee's proposal, that the board of directors shall consist of six (6) ordinary members without deputies and that one registered auditing company is appointed as auditor until the end of the next annual general meeting.
The general meeting resolved, in accordance with the nomination committee's proposal, to re-elect the registered auditing company
Determination of remuneration for the members of the board of directors and the auditors
The general meeting resolved, in accordance with the nomination committee's proposal, that remuneration for the board of directors, excluding remuneration for committee work, shall be paid with a total of
The general meeting resolved, in accordance with the nomination committee's proposal, that remuneration to the auditor shall be paid in accordance with approved invoices.
Authorization for the board of directors to issue new shares
The general meeting resolved, in accordance with the board of directors' proposal, to authorize the board of directors to, until the next annual general meeting, on one or more occasions, resolve to increase the company's share capital by issue of shares corresponding to no more than ten (10) per cent of the total number of shares in the company at the time of the meeting's decision of authorization. The board of directors may deviate from the shareholders' preferential rights. The reason for the board of directors' authorization to deviate from the shareholders' preferential rights is to enable the company to raise new capital and to take advantage of future opportunities to attract new long-term owners, and to finance the company's growth strategy. The authorization also includes the right to decide on payment for the issued shares by set-off, in kind or with other conditions as referred in Chapter 13 Section 5 item 6 of the Swedish Companies Act (Sw. Aktiebolagslagen (2005:551)). At a deviation from the shareholders' preferential rights, the issue rate shall be determined in accordance with market conditions, taking into account any discount on market terms.
For more detailed information regarding the content of the resolutions, please refer to the press release published on
For more information please contact:
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Phone: +46 (0)708 55 11 85 | Email: stefan.olsson@enzymatica.com
For more information, please visit www.enzymatica.se.
https://news.cision.com/enzymatica-ab/r/bulletin-from-annual-general-meeting-of-enzymatica-ab--publ-,c3764168
https://mb.cision.com/Main/18091/3764168/2034557.pdf
(c) 2023 Cision. All rights reserved., source